HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and anti-tumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address tumor metastasis, treatment resistance, and cancer relapse; all significant drivers of cancer-related deaths. Our product candidates HC-5404 and HC-7366, both completing Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently in Phase 2 clinical development, modulates the anti-tumor innate immune response.
| Website | https://www.hibercell.com/ |
| Revenue | $11.6 million |
| Employees | 26 (19 on RocketReach) |
| Founded | 2019 |
| Address | 619 West 54th Street 8th Floor, New York, New York 10019, US |
| Phone | +1 651-675-0300 |
| Technologies |
JavaScript
,
HTML
,
PHP
+12 more
(view full list)
|
| Industry | Biotechnology Research, Biotechnology, Science and Engineering |
| Keywords | Precision Oncology, Oncology, First In Class, Cancer Treatment, Clinical Stage, Cancer Therapies, Immuno Oncology, Targeted Therapy, Drug Development, Biotechnology, Pharmaceutical, Therapeutic Agents, Cancer Research, Clinical Trials, Molecular Pathways, Biopharma |
| Competitors | Roche, Novartis, Pfizer, Sanofi, GSK, AstraZeneca, Bristol Myers Squibb, Amgen, Regeneron, Lilly India +48 more (view full list) |
Looking for a particular HiberCell employee's phone or email?
The HiberCell annual revenue was $11.6 million in 2026.
Jonathan L is the President and Chief Executive Officer of HiberCell.
19 people are employed at HiberCell.
HiberCell is based in New York, New York.